EUVIMEDEUVIMED entdecken
Crossref

T cell costimulatory blockade ameliorates induction of experimental membranous nephropathy potentially through T-helper 17 cell suppression in the kidney

Edmund Y M Chung iD, Yuan Min Wang, Karli Shaw, Emily Ronning, Ya Wang, Geoff Yu Zhang, Min Hu, Karen Keung, Hugh J McCarthy, David C H Harris, Stephen I Alexander

Nephrology Dialysis Transplantation · 2025

DOI: 10.1093/ndt/gfaf030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2025. Verfasst von Edmund Y M Chung und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Kidney Research, Children's Hospital at Westmead, Westmead, NSW, Australia. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Th17 Cells, Pyrazines, Immunoconjugates. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Health and Medical Research Council of Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and hypothesis Recent advances in membranous nephropathy treatment have focused on B cell depletion, which is incompletely effective, potentially due to persistent autoantibody-producing plasma cells or alternative pathways of injury. T cell costimulatory blockade [cytotoxic-T-lymphocyte-associated antigen 4 (CTLA4)-Ig] to prevent T cell-dependent B cell activation and short-course proteasome inhibition (bortezomib) to deplete plasma cells may represent a complementary form of treatment.

Methods

Lewis rats were immunized with Fx1A and complete Freund's adjuvant to induce experimental membranous nephropathy (Heymann nephritis or HN) and treated with CTLA4-Ig alone or CTLA4-Ig plus a short-course of bortezomib. Serum creatinine, proteinuria, kidney histology, serum anti-Fx1A levels, kidney and spleen messenger RNA expression, and flow cytometry on splenocytes were evaluated at 12 weeks.

Results

CTLA4-Ig-treated and CTLA4-Ig plus bortezomib-treated rats had significant and similar reductions in serum creatinine and proteinuria, with less histological kidney injury compared with untreated HN rats. Glomerular IgG deposition was reduced in CTLA4-Ig-treated and CTLA4-Ig plus bortezomib-treated rats compared with untreated HN rats but there were no significant differences in serum anti-Fx1A levels. CTLA4-Ig-treated and CTLA4-Ig plus bortezomib-treated rats exhibited significantly reduced T helper (Th)-17 cell cytokines (interleukin-6, -17, -21) and regulatory T cell (Foxp3, TGF-β) expression in the kidney but not the spleen. Immunohistochemical staining of CD4+ and intracellular STAT3+ cells was reduced in CTLA4-Ig plus bortezomib-treated and CTLA4-Ig-treated compared with untreated HN rats. On flow cytometry, CTLA4-Ig reduced B cells and plasma cells but not T cell subsets.

Conclusions

CTLA4-Ig ameliorated induction of experimental membranous nephropathy, potentially through suppression of Th17 cells in the kidney, and may represent an effective adjunct treatment in membranous nephropathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, MembranousTh17 CellsPyrazinesImmunoconjugatesKidneyAnimalsRatsBortezomibAbataceptRats, Inbred LewBoronic AcidsMaleLymphocyte Activation

Stichwörter der Autor:innen

CTLA4-IgHeymann nephritisT cell costimulatory blockadeTh17 cellsmembranous nephropathy

Substanzen

BortezomibAbataceptBoronic AcidsPyrazinesImmunoconjugates

Autor:innen und Institutionen

  • Centre for Kidney Research, Children's Hospital at Westmead, Westmead, NSW, Australia.
  • Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.
  • Centre for Transplant and Renal Research, Westmead Institute for Medical Research, Westmead, NSW, Australia.
  • Department of Nephrology, Prince of Wales Hospital, Randwick, NSW, Australia.

ORCID-Profile: Edmund Y M Chung

Förderung

  • National Health and Medical Research Council of Australia

Zitieren

APA

Chung, E. Y. M., Wang, Y. M., Shaw, K., Ronning, E., Wang, Y., Yu Zhang, G., Hu, M., Keung, K., McCarthy, H. J., Harris, D. C. H., & Alexander, S. I. (2025). T cell costimulatory blockade ameliorates induction of experimental membranous nephropathy potentially through T-helper 17 cell suppression in the kidney. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaf030

Vancouver

Chung EYM, Wang YM, Shaw K, Ronning E, Wang Y, Yu Zhang G, et al. T cell costimulatory blockade ameliorates induction of experimental membranous nephropathy potentially through T-helper 17 cell suppression in the kidney. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfaf030

BibTeX
@article{Chung2025,
  author = {Chung, Edmund Y M and Wang, Yuan Min and Shaw, Karli and Ronning, Emily and Wang, Ya and Yu Zhang, Geoff and Hu, Min and Keung, Karen and McCarthy, Hugh J and Harris, David C H and Alexander, Stephen I},
  title = {T cell costimulatory blockade ameliorates induction of experimental membranous nephropathy potentially through T-helper 17 cell suppression in the kidney},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  doi = {10.1093/ndt/gfaf030}
}
Kostenlos starten →